TBCRC Patient Advocate Working Group
The Translational Breast Cancer Research Consortium (TBCRC) is a collaborative group founded in 2005 to conduct innovative and high‐impact clinical trials for breast cancer.
The TBCRC consists of 14 research centers, with member personnel representing clinicians, basic scientists, statisticians, and patient advocates. TBCRC trials not only test novel, laboratory based strategies, but also attempt to understand the underlying cause and biology of breast cancer.The TBCRC advocates are women who have survived breast cancer and now want to help other breast cancer patients through assuring the patient voice is heard and valued by researchers.
For more information about the Translational Breast Cancer Research Consortium (TBCRC) http://pub.emmes.com/study/bcrc/